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ABSTRACT 
 
COVID-19 has created a global pandemic with high morbidity and mortality in 2020. Novel coronavirus (nCoV), also 
known as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2), is responsible for this deadly disease. 
International Committee on Taxonomy of Viruses (ICTV) has declared that nCoV is highly genetically similar to SARS-
CoV epidemic in 2003 (∼ 89% similarity). Limited number of clinically validated Human-nCoV protein interaction data is 
available in the literature. With this hypothesis, the present work focuses on developing a computational model for nCoV-
Human protein interaction network, using the experimentally validated SARS-CoV-Human protein interactions. Initially, 
level-1 and level-2 human spreader proteins are identified in SARS-CoV-Human interaction network, using Susceptible-
Infected-Susceptible (SIS) model. These proteins are considered as potential human targets for nCoV bait proteins. A gene-
ontology based fuzzy affinity function has been used to construct the nCoV-Human protein interaction network at ∼ 
99.98% specificity threshold. This also identifies the level-1 human spreaders for COVID-19 in human protein-interaction 
network. Level-2 human spreaders are subsequently identified using the SIS model. The derived host-pathogen interaction 
network is finally validated using 7 potential FDA listed drugs for COVID-19 with significant overlap between the known 
drug target proteins and the identified spreader proteins. 
 
Introduction 
 
COVID-19 evolved in the Chinese city of Wuhan (Hubei province)1. The first case of human species getting 
affected by nCoV was observed on 31 December 20192. Soon it expands its adverse effect on almost all 
nations within a very short span of time3. World Health Organization (WHO) observes that the massive 
disastrous outbreak of nCoV is mainly due to mass community spreading and declares a global health 
emergency on 30 January 20204. After proper assessment, WHO presumes its fatality rate to be 4%5 which urges 
the global researchers to work together to discover a proper treatment for this pandemic6, 7. Coronaviridae is the 
family to which a corona virus belongs. It also infects birds and mammals besides affecting human beings. 
Though the common symptoms of corona virus are common cold, cough etc., but it is accompanied by severe 
acute chronic respiratory disease along with multiple organ failure leading to human death. Severe Acute 
Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS) are the two major outbreaks in 
2003 and 2012 respectively before SARS-CoV2. The source of origin of SARS was located in Southern China. 
Its fatality rate was within 14%-15%8 due to which 774 people lost their lives among 8804 affected cases. Saudi 
Arabia was marked as the base for the commencement of MERS. 858 persons among 2494 infected cases were 
defeated in their battle against MERS virus. Thus it generated a much higher fatality rate of 34.4%9 when 
compared to that of SARS. All of the three epidemic creators SARS, MERS and SARS-CoV2 are biologically 
included in the genus Betacoronavirus which is under the family Coronaviridae. Both structural and non-
structural proteins are involved in the formation of SARS-CoV2. Out of the two, structural proteins like the 
envelope (E) protein, membrane (M) protein, nucleocapsid (N) protein and the spike (S) protein play a major 
role in transmitting the disease by binding with the receptors after entering into human body10 . No clinically 
proven and approved vaccine for nCoV is available till date though researchers have been trying hard to develop 
it. So there is an urgent need to understand and analyse the mechanism of disease transmission of this new virus. 
 
 
 
Host-pathogen protein-protein interaction networks (PPIN) are very significant for understanding the mechanism of 
transmission of infection, which is essential for the development of new and more effective therapeutics, including 
rational drug design. Progression of Infection and disease results in due to the interaction of proteins in between 
pathogen and host. Pathogen plays an active role in spreading infection.  It has been proved to be an acute threat to 
human lives as it has the mutative capability to adapt itself toward drugs. Pathogen and host PPIN permits 
pathogenic microorganisms to utilize host capabilities by manipulating the host mechanisms in order to abscond 
from the immune responses of the host11–13. Detection of target proteins through the analysis of pathogen and host 
PPIN is the central point of research study14, 15. Topologically significant proteins having higher degree of 
interactions are generally found to be essential drug targets. However, proteins having less number of interactions 
or topologically not significant may be involved in the mechanism of infection because of some biological pathway 
relevance. 
However, clinically validated Human-nCoV protein interaction data is limited in the current literature. This has 
motivated us to develop a new computational model for nCoV-Human PPI network. We have subsequently 
validated the proteins involved in the host-pathogen interactions with respect to potential Food and Drug 
Administration (FDA) drugs for COVID-19 treatment. Key aspects of this research work are highlighted below: 
• It has been reported that SARS-CoV has ∼ 89%16, 17 genetic similarities with nCoV. 
• SARS-CoV-Human protein-protein interaction network has also been studied widely and available in 
literature18–20. 
• Recently we have developed a computational model to identify potential spreader proteins in a 
Human-SARS CoV interaction network using SIS model21. 
• Sequence information of some of the nCoV proteins have been released22. 
• Gene ontological (GO) information (Biological Process (BP), Molecular Function (MF), Cellular 
Component (CC)) of some of the nCoV proteins are also available22, 23. 
• Recently we have also developed a method to predict interaction affinity between proteins from the 
available GO graph.24. 
• Assessment of interaction affinity between nCoV proteins with potential Human target/bait proteins, which 
are susceptible to SARS-CoV infection, has been done. 
• Fuzzy affinity thresholding is done to detect High Quality nCoV-Human PPIN. The selected human 
proteins are considered as level-1 human spreader nodes of nCoV. 
• Level 2 spreader node in nCoV-Human PPIN are detected using spreadability index and validated by 
SIS21, 25 model. 
• Validation of our developed model is done with respect to the target proteins of the potential FDA drugs 
for COVID-19 treatment.26 
 
Results 
 
Our developed computational model of nCoV-Human PPIN contains high quality interactions (HQI) and proteins 
identified by Fuzzy affinity thresholding and spreadability index validated by SIS model respectively. Sources 
of input and the generated results always play a crucial role in any computational model which is also true for 
our proposed model. 
Overview of the data sets 
SARS-CoV-Human PPIN serves as a baseline for our model. The potential level-1 and level-2 human 
spreaders of SARS-CoV becomes the possible candidate set for selecting level-1 human spreaders of SARS-
CoV2. Various datasets have been curated for this purpose which has been outlined below: 
 
Human PPIN 
The dataset27, 28 consists of all possible interactions between human proteins that are experimentally 
documented in humans. Human proteins are represented as nodes while the physical interactions between 
proteins are represented by edges. It is a collection of 21557 nodes and includes 342353 edges/interactions. 
 
SARS-CoV PPIN 
 
The dataset18 consists of interactions between SARS-CoV proteins. It contains 7 unique proteins along with the 
involvement of 17 interacting edges out of which only the densely connected proteins are considered rather 
than the isolated ones since the former play a more active role in transmission of infection than the later. 
 
SARS-CoV-Human PPIN 
 
The dataset18 comprises of 118 interactions between SARS-CoV and Human. It is used to fetch the level-1 
human interactions of SARS-CoV. 
 
 
Figure 1. Computational model for the selection of spreader nodes in Human-SARS CoV PPIN by 
spreadability index. Red colored nodes represent SARS-CoV proteins while blue colored nodes are the selected 
spreader nodes in it. Deep green colored nodes represent level-1 human connected proteins with SARS-CoV 
proteins while yellow colored nodes represent the selected human spreaders in it. Light green colored nodes 
represent level-2 human spreaders of SARS-CoV. 
 
SARS-CoV2 Proteins 
 
This data is collected from pre-released dataset of available SARS-CoV2 protein from UniProtKB22 (https://covid-
19.uniprot.org/) which include 14 reviewed SARS-CoV2 proteins. 
 
GO Graph and Protein-GO annotations 
 
Three types (CC, MF and BP) of GO graph are collected from GO Consortium23, 29 
(http://geneontology.org/). Protein to GO-annotation map is retrieved from UniProtKB database. 
 
Potential COVID-19 FDA drugs 
 
Seven potential FDA drugs : Lopinavir30, Ritonavir31, Hydroxychloroquine32, 33, Azithromycin33, 
Remdesivir34–36, Favipi- ravir37, 38 and Darunavir39 have been identified from the DrugBank40 published white 
paper26 which have been used for validation in our proposed model. 
 
Selection of spreader nodes in Human-SARS CoV interaction network using spreadability 
index validated by SIS model: 
SARS-CoV-Human PPIN (up to level-2) is formed by the combination of SARS-CoV-Human and Human-
Human PPIN datasets. SARS-CoV-Human dataset generates the direct level-1 human interactions of SARS-CoV 
while human-Human PPIN dataset is used to fetch the corresponding level-2 human interactions. Potential 
spreader nodes are identified using spreadability index which has been validated by SIS model (see Figure 1)21. 
The selected spreader nodes in SARS-COV-Human PPIN are highlighted in Table S1, Table S2 and Table S3 
in the supplementary document. The network view of SARS-CoV-Human PPIN at each level and various 
selected thresholds are also available online (SARS-CoV Level-1 human spreaders, Level-1 & Level-2:high 
human spreaders at high threshold of spreadability index, and Level-1 & Level-2:low human spreaders at low 
threshold of spreadability index). 
 
Figure 2. Schematic diagram of Fuzzy PPI model. A) The fuzzy PPI model finds the interaction affinity 
between the SARS-CoV2 and Human proteins (L1 and L2 spreader of SARS-CoV) using gene ontological 
information. B) All GO pair-wise interaction affinities are assessed from three independent GO-relationship 
graphs CC, MF and BP and fuzzy binding affinity of a protein pair is computed from all three pairwise scores of 
all GO-pair affinities. C) Heatmap representation of Fuzzy PPI score. D) Network representation of Human and 
SARS-CoV2 proteins with 0.2 onward threshold of Fuzzy PPI score at high specificity. Finally, high quality 
interactions are extracted to retrieve the potential human prey for SARS-CoV2 at 1.4 threshold. 
 
 
Figure 3. Network representation of HQIs (score≥ 0.4) between SARS-CoV2 and human proteins. Blue and 
yellow spherical nodes represent the SARS-CoV2 and human proteins respectively. The edge width reflects 
the fuzzy score of binding affinity. 
Identification of the nCoV-Human proteins interactions using Fuzzy PPI model: 
The GO information can be useful to infer the binding affinity of any pair of interacting proteins using three 
different types of GO hierarchical relationship graph (CC, MF and BP)23. The fuzzy PPI model has been 
proposed to find the interaction affinity between the SARS-CoV2 and Human proteins using GO based 
information (please see Figure 2 and Methods for details). To identify the interactors of SARS-CoV2 on human 
using the Fuzzy PPI model, a set of candidate proteins are selected as the L1 and L2 spreader nodes of SARS-
CoV using SIS model (as depicted in Figure 1). Fuzzy PPI model is constructed from the ontological 
relationship graphs by evaluating the affinity between all possible GO pairs annotated from any target protein 
pair and finally the fuzzy score of interaction affinity of protein pair is computed from these GO pair-wise 
interaction affinity in to a range of [0,1] (details are discussed in the Methods). The heatmap representation of 
fuzzy interaction affinities (with score ≥ 0.2 for very high specificity ~ 99%) is shown in supplementary Figure 
S1 and Table S4. The high quality interaction (HQI) is retrieved at threshold 0.4, (almost ~ 99.98% 
Specificity) which results total 78 interactions between SARS-CoV2 and Human (37 proteins). The interaction 
networks predicted from Fuzzy-PPI model are shown in Figure 3.  
 
Identification of Human spreader proteins for nCoV 
Human proteins present in the high quality interactions of nCoV-Human PPIN fetched by applying fuzzy affinity 
threshold are considered as level-1 spreaders. From these level-1 spreaders, corresponding level-2 human 
interactions are obtained using human-Human PPIN dataset. Spreadability index is thus computed for these 
level-2 human proteins for the identification of level-2 human spreader nodes. The selection is also verified by 
SIS model. The selected spreader nodes in SARSCOV-Human PPIN are highlighted in Table S4, Table S5 and 
Table S6 in the supplementary document. A sample computational model 
 
 
 
Figure 4. Derived nCoV-Human PPIN with human spreader proteins from proposed computational model. 
Blue, yellow and green colored nodes denote nCoV spreaders, its human level-1 and level-2 spreaders. level-1 
human spreaders are detected by applying fuzzy affinity thresholding while level-2 human spreaders are 
identified by spreadability index validated by SIS model. 
 
Figure 5. Validation of our developed computational model with respect to the target proteins of the FDA 
accepted drugs for COVID-19 treatment. Yellow and green colored nodes denote level-1 and level-2 human 
spreader of nCoV which acts as the drug protein targets. 
 
of nCoV-Human PPIN under high threshold has been highlighted in Figure 4. The network view of SARS-
CoV2-Human PPIN at each level and various selected thresholds are also available online (SARS-CoV2 Level-1 
human spreaders, Level-1 & Level-2:high spreaders at high threshold of spreadability index and Level-1 & 
Level-2:low human spreaders at low threshold of spreadability index). 
 
Validation using potential FDA drugs for COVID-19: 
After proper assessment of all potential drugs as mentioned in the DrugBank40 white paper26, seven 
drugs Lopinavir30, Ritonavir31, Hydroxychloroquine32, 33, Azithromycin33, Remdesivir34–36, Favipiravir37, 38 
and Darunavir39 are identified which are showing expected results to some extent in the clinical trials done for 
SARS-CoV2 vaccine till date. All approved human protein targets for each of the five approved drugs are 
fetched from the advanced search section41 of drug bank40, 42. These targets when searched in our proposed 
model of nCoV-Human PPIN are found to play an active role of spreader nodes. This reveals the fact that the 
selected spreader nodes are of biological importance in transmitting infection in a network which actually make 
them the protein drug targets of the potential FDA drugs for COVID-19. The target protein hits in our nCoV-
Human PPIN for each of the 7 potential FDA drugs are highlighted in Figure 5. It can be observed that 4 target 
protein hits are obtained for Hydroxychloroquine, 3 target proteins for Ritonavir, 2 target protein hits for each of 
Lopinavir, Darunavir and Azithromycin and 1 target protein hit for Remdesivir and Favipiravir. Out of these 
protein targets, ACE2 is the most important one since it is considered to be the one of the crucial receptors of 
human for nCoV to transmit infection deep inside the human cell43–45. 
 
Discussion 
 
In any host-pathogen interaction network, identification of spreader nodes is crucial for disease prognosis. Not 
every protein in an interaction network has intense disease spreading capability. In this work, we have used the 
SARS-CoV-Human PPIN network and the spreader nodes at both level-1 and level-2 using the SIS model. 
These spreader nodes are considered for computing the protein interaction affinity score to unmask the level-1 
human spreaders of nCoV. GO annotations have been also taken into consideration along with PPIN properties 
to make this model more effective and significant. With the gradual progress of the work, it has been observed 
that the selected human spreader nodes, identified by our proposed model, emerge as the potential protein 
targets of the FDA approved drugs for COVID-19. The basic hypotheses of the work may be listed as follows: 
 
  
Figure 6. Specificity at different threshold (x-axis) of binding affinity obtained from Fuzzy PPI model for 
complete human proteome interaction network. At 0.2 onward threshold, it produces high specificity with 
respect to benchmark positive and negative interaction data. High quality interactions are extracted at 0.4 
threshold with ~ 99.9% specificity. 
 
• There is a genetic overlap of ~ 89% (as suggested by ICTV) between SARS-CoV and SARS-CoV2, 
which also leads to a significant overlap in spreader proteins between human-SARS-COV and human-
SARS-COV2 protein-interaction network. 
• Fuzzy PPI approach can assess protein interaction affinities at very high specificity with respect to 
benchmark datasets 
as shown in Figure 6. High specificity signifies very low false positive rate at a given threshold. Thus, at 
0.4 threshold (~ 99.9% specificity), the proposed model evaluates high quality positive interactions in 
Human-nCoV PPIN. 
 
Finally we propose, that the developed computational model effectively identifies Human-nCoV PPIs with 
high specificity. nCoV-Human interactions are inferred from another pandemic initiator SARS-CoV which is 
believed to be highly genetically similar to nCoV. We also identify the human spreader proteins (up to level-2) 
using spreadability index, validated through SIS model. Due to high network density in human interaction 
network, number of proteins increase with the transition from one level to another. So, our proposed model is 
also capable of identifying human spreader proteins in level-2 by using spreadability index which is validated 
by SIS model. 
Target proteins of the potential FDA drugs for COVID-19 are found to overlap with the spreader nodes of 
the proposed computational nCoV-Human protein interaction model. Target proteins of seven potential FDA 
drugs: Lopinavir30, Ritonavir31, Hydroxychloroquine32, 33, Azithromycin33, Remdesivir34–36, Favipiravir37, 38 
and Darunavir39 for COVID-19 as mentioned in the DrugBank white paper26 overlap with the spreader nodes 
of the proposed in silico nCoV-Human protein interaction model (see Figure 5). Though clinical trials for 
COVID-19 vaccine in 2020 are on their way till date but three out of the seven i.e. Remdesivir46 
Hydroxychloroquine47 and Favipiravir47 are found to be the most promising as well as effective ones and 
their protein targets R1AB_SARS2, TLR9, ACE2, CYP3A4 and ABCB1 are also successfully identified as 
spreader nodes by our proposed model. This assessment reveals the fact that these spreader nodes are indeed 
have biological relevance relative to disease propagation. 
 
Methods 
Our developed computational model for nCoV-Human PPIN consists of two important methodologies 1) 
identification of spreader nodes by spreadability index along with the validation of SIS model and 2) Fuzzy PPI 
model. 
 
Identification of spreader nodes by spreadability index along with the validation of SIS model: 
In nCoV-Human PPIN, the former acts as a pathogen while the host acts as bait. The transmission of infection 
starts when a pathogen enters a host body and starts infecting its protein which in turn affects its directly or 
indirectly connected neighborhood proteins. Considering this method of transmission, PPIN of human and 
SARS-CoV are considered to detect spreader nodes. Spreader nodes are those nodes proteins which actually 
transmits the disease fast among its neighbors. But not all the nodes in a PPIN are spreaders.  So, proper 
detection of spreader nodes is crucial.  Thus, spreader nodes are identified by spreadability index which 
actually measure the transmission capability of a node protein. 
 
 
 
Figure 7. Synthetic protein-protein interaction network. It is comprised of 10 nodes and 25 edges. 
 
Table 1. Computation of spreadability index of Figure 7 along with validation of selected top 5 spreader nodes 
by SIS model. 
 
Rank Proteins     
      
   
Edge 
Ratio 
Neighborhood 
Density 
Node 
Weight 
Spreadability 
Index 
Sum of SIS 
infection rate of 
top 5 nodes 
1 Node 3 6 3 1.75 6.94 2.83 14.99 
1.19 
2 Node 9 5 4 1.20 7.07 3.00 11.48 
3 Node 6 5 2 2.00 3.93 2.60 10.46 
4 Node 8 6 2 2.33 2.27 3.25 8.55 
5 Node 1 5 4 1.20 4.21 3.40 8.45 
 
Compactness of PPIN and its transferal capability is evaluated using centrality analysis. Nodes having high 
centrality value are usually considered as spreader nodes or the most critical node in a network. 
 
Spreadability index21 is one of the centrality based measure which is a combination of three major topological 
neighborhood based features of a network. They are: 1) Node weight
48
 2) Edge ratio
49
 and 3) Neighborhood 
density
49
. Nodes having high spreadability index are considered as spreader nodes. The spreader nodes thus 
identified are also validated by SIS model
25
. SIS model is implemented with a motive of designing the SARS-
CoV and SARS-CoV2 outbreak into a disease model consisting of proteins based on their present infection 
status. A protein can be in either of one of the three states: 1) S: Susceptible, which means that every protein is 
initially susceptible though it is not yet infected but is at risk of getting infected by disease. 2) I: Infected, which 
means that the protein is already infected by the disease and 3) S: Susceptible, which means proteins again 
become susceptible after getting recovered from infected state. This model is implemented in such a way that it 
generates the overall infection capability of a node after a certain range of iterations. Thus the sum of the 
infection capability of the top selected spreader nodes are computed by this model which is compared against 
the sum obtained for the selected top critical nodes by other existing centrality measures like Betweenness 
Centrality (BC)
50
, Closeness centrality (CC)
51
, Degree centrality (DC)
52
 and Local average centrality (LAC)
53
. 
Our proposed method of selecting spreader nodes21 has performed better in comparison to the other existing 
state-of-the-art. A synthetic PPIN is considered in Figure 7 to demonstrate the entire methodology of 
spreadability index. Computational analysis of spreadability index of our proposed model with one of the other 
methodology BC has been highlighted from Table 1 to supplementary Table S7.      
   is the total number of 
edges which are outgoing from the ego network     whereas    
   is denoted as the total number of 
interconnections in the neighborhood of node  49.      
   of node 3 is 6 while    
   of node 3 is 3 which 
highlights the fact that node 3 has the highest transmission ability from its ego network to outside when 
compared to other nodes. Node 3 has also the highest spreadability index. But BC failed to rank node 3 in first 
position. Same scenario can be observed for some other nodes in the synthetic network too. Besides SIS 
validation result shows that the selected top ranked spreader nodes in this proposed model have the highest 
infection capability in comparison to the other ranked nodes. 
 
Fuzzy PPI Model for potential SARS-CoV2-Human interaction identification: 
The binding affinity between any two interacting proteins can be estimated by combining the semantic similarity 
scores of the GO terms associated with the proteins15, 24, 54–56. Greater number of semantically similar GO 
annotations between any protein pair indicates higher interaction affinity. Fuzzy PPI model is a hybrid 
approach24 that utilizes both the topological57 features of the GO graph and information contents56, 58, 59 of the 
GO terms. 
GO is organized in three independent directed acyclic graphs (DAGs): molecular function (MF), biological 
process(BP), and cellular component(CC)23. The nodes in each GO graph represent GO terms and the edges 
represent different hierarchical relationships. In this work, two most important relations ‘is a’ and ‘part of’ has 
been used for GO relations29. 
The semantic similarity between any two proteins is estimated by considering the similarities between their 
all pairs of annotating gene ontology (GO) terms belonging to a particular ontological graph. The similarity of a 
GO term pair is determined by considering certain topological properties (shortest path length) of the GO graph 
and the average information content (IC)60 of the disjunctive common ancestors (DCAs)54, 55 of the GO terms as 
proposed in24. Fuzzy PPI first rely on a fuzzy clustering of the GO graph where the selection of GO terms as 
cluster center is based on the level of association of that GO term in the GO graph. The cluster centers are 
selected based on the proportion measure of GO terms. The proportion measure for any GO term t is computed 
as    ( )  (|  ( )|  |  ( )|) | ( )|⁄ where   ( ) ,  ( ) represents the ascendant and descendant of 
term    and ( )  is  the  total  number  of  GO  terms  in  ontology O. Higher value of proportion measure 
signifies higher coverage of ascendants and descendants associated with the specific node. The GO terms for 
which this proportion measure is above a predefined threshold are selected as cluster centers. In this work, the 
cluster centers are selected based on the threshold values as suggested in 15, 24.  
After selecting the cluster centers, the degree of membership of a GO term to each of the selected cluster 
centers is calculated using its respective shortest path lengths to the corresponding cluster centers. The 
membership of the GO term to a cluster decreases with increase in its shortest path length to the cluster center. 
The membership function is defined as    ( )   
 (    )
    ⁄   where    is      center and   is the width of 
membership function and   is the shortest path length from   to   . The difference in membership values 
between the GO pair   and    with respect to each cluster center, are computed to find the weight parameter. 
The weight parameter is defined as   (     )        (     ). This weight value determines how 
dissimilar two GO terms can be with respect to the cluster centers. Next, the shared information content (SIC) 
is computed using average IC60, of the DCAs of GO term pair (     ) is determined from three GO graphs.  
The SIC is defined as    (     )  ∑   ( )     (     ) |   (     )|⁄ , where    (     ) represents the 
disjunctive common ancestors of GO-term    and   .The semantic similarity of protein pair (      ) for each 
GO-type (CC, MF and BP), is estimated by utilizing the maximum similarity of all possible GO pairs from the 
annotations of proteins    and    for each type of GO. The binding affinity of protein pair (      ) is defined as 
the average of CC, MF and BP based semantic similarity. The fuzzy score of binding affinity is computed by 
normalizing the binding affinity using max-min normalization. In this work, the fuzzy binding affinity score is 
computed between the protein pairs of SARS-CoV2 and human proteins using the available ontological 
information. Finally, with high specificity threshold (please see Figure 6), high quality interactions are 
extracted for human-SARS-CoV2. 
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